Study shows that dosage of Amgen drug is higher in for-profit dialysis
A recent study showed that big for-profit dialysis chains give far higher doses of anemia drugs to their kidney patients than do nonprofit centers. The study found that for-profit dialysis chains may dose some patients with the Amgen drug at levels up to three times as high as nonprofit centers.
For the full article.
Bookmark: 
